Glytec Receives Five Additional Patent Allowances for its Diabetes Therapy Management Software
Glytec, the healthcare company behind a market-leading software solution for personalized diabetes therapy management, announces five new patent allowances for its eGlycemic Management System (eGMS), increasing the company’s portfolio to a total of 11 allowed or issued patents, with more than 50 pending.
Three of the new allowances were issued by the United States Patent and Trademark Office and two by the Israel Patent Office. The patents apply to proprietary systems and methods for intravenous and subcutaneous insulin therapies. They also address eGMS integration with connected device systems — such as those which host and/or store blood glucose data — as well as enterprise health information systems, including electronic medical record systems (EMR); laboratory information systems (LIS); and admission, discharge and transfer systems (ADT).
“Technology innovation is one of Glytec’s core competencies, and it’s a significant investment for the company,” says Glytec’s Senior Vice President Research and Development, Robby Booth. “Our intellectual property protections, both here in the U.S. and abroad, speak to the unique and highly differentiated characteristics of our eGlycemic Management System. Though, the improved clinical outcomes our clients achieve, and the associated cost savings, are the true testament of its worth.”
Glytec’s President and CEO, Bob Leonard adds: “A recent case study published by one of our clients — a large regional academic medical center — shows annualized savings in excess of $9.7 million using eGMS to achieve best practice and reduce incidence of hypoglycemia for hospitalized patients. In other studies, we’ve demonstrated how using eGMS leads to a decrease in readmissions of 35-68% and a sustained drop in A1C levels of 2.6 percentage points for chronic care populations, both of which result in improved quality of care and great economic benefit, especially in light of alternative reimbursement models. eGMS is an enabling solution of value to health systems, payers and patients alike.”
Statistics from myriad organizations, including American Diabetes Association, International Diabetes Federation, and World Health Organization, point to the fact that diabetes is a global epidemic. “The difficulties associated with diabetes therapy management, especially insulin dosing and titration, are universal,” says Leonard. “Our intensive pursuit of both domestic and international patents formidably positions Glytec for broad geographic growth.”